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disease development or progression. In this review, we 
will discuss literature and bioinformatic data describing 
the involvement of CNVs on PD pathobiology. We will 
analyze the most frequent copy number changes in famil-
iar PD genes and provide a “systems biology” overview 
of rare individual rearrangements that could function-
ally act on commonly deregulated molecular pathways. 
Assessing the global genome-wide burden of CNVs in 
PD patients may reveal new disease-related molecular 
mechanisms, and open the window to a new possible 
genetic scenario in the unsolved PD puzzle.
Abbreviations
ABL1  ABL proto-oncogene 1, non-receptor tyros-
ine kinase
ADCYAP1  Adenylate cyclase-activating polypeptide 1
ATP13A2  ATPase 13A2
ATXN3  Ataxin 3
BCHE  Butyrylcholinesterase
BCL2  Apoptosis regulator
CHCHD3  Coiled-coil-helix-coiled-coil-helix domain 
containing 3
CNTNAP2  Contactin-associated protein-like 2
CNVs  Copy number variations
COMT  Catechol-O-methyltransferase
CUL5  Cullin 5
D1R  Dopamine receptor D1
DACH1  Dachshund family transcription factor 1
DDOST  Dolichyl-diphosphooligosaccharide–protein 
glycosyltransferase non-catalytic subunit
DGCR8  DGCR8 microprocessor complex subunit
DLC1  DLC1 Rho GTPase-activating protein
DLG1  Discs large MAGUK scaffold protein 1
DOCK5  Dedicator of cytokinesis 5
FBXO7  F-box protein 7
Abstract Parkinson’s disease (PD), the second most 
common progressive neurodegenerative disorder of 
aging, was long believed to be a non-genetic sporadic 
origin syndrome. The proof that several genetic loci are 
responsible for rare Mendelian forms has represented a 
revolutionary breakthrough, enabling to reveal molecu-
lar mechanisms underlying this debilitating still incur-
able condition. While single nucleotide polymorphisms 
(SNPs) and small indels constitute the most commonly 
investigated DNA variations accounting for only a lim-
ited number of PD cases, larger genomic molecular rear-
rangements have emerged as significant PD-causing 
mutations, including submicroscopic Copy Number Vari-
ations (CNVs). CNVs constitute a prevalent source of 
genomic variations and substantially participate in each 
individual’s genomic makeup and phenotypic outcome. 
However, the majority of genetic studies have focused 
their attention on single candidate-gene mutations or on 
common variants reaching a significant statistical level 
of acceptance. This gene-centric approach is insufficient 
to uncover the genetic background of polygenic multi-
factorial disorders like PD, and potentially masks rare 
individual CNVs that all together might contribute to 
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FBXW7  F-box and WD repeat domain containing 7
FISH  Fluorescent in situ hybridization
FoSTeS  Fork stalling and template switching
FPR3  Formyl peptide receptor 3
FTLDU-17  Ubiquitin-positive frontotemporal lobar 
degeneration linked to chromosome 17
GAK-DGKQ  Cyclin G-associated kinase-diacylglycerol 
kinase theta
GBA  Glucosylceramidase beta
GBAP1  Glucosylceramidase beta pseudogene 1
GNB1L  G protein subunit beta 1 like
GRID1  Glutamate ionotropic receptor delta type 
subunit 1
GRIP1  Glutamate receptor interacting protein 1
GRN  Granulin
HNF1B  HNF1 homeobox B
HSF1  Heat-shock transcription factor 1
HTRA2  HtrA serine peptidase 2
IGF1  Insulin growth factor 1
IGF1R  Insulin-like growth factor 1 receptor
KCNJ12  Potassium voltage-gated channel subfamily 
J member 12
KLC1  Kinesin light chain 1
LHX1  LIM homeobox 1
LRRK2  Leucine-rich repeat kinase 2
MAPT  Microtubule-associated protein tau
MBD3  Methyl–CpG binding domain protein 3
NAHR  Non-allelic homologous recombination
NAT8L  N-Acetyltransferase 8 like
NHEJ  Non-homologous end joining
NRSN1  Neurensin 1
NRXN1  Neurexin 1
NSF  N-Ethylmaleimide-sensitive factor, vesicle 
fusing ATPase
OVOS2  Ovostatin 2
PACAP  Pituitary adenylate cyclase-activating 
polypeptide
PARK10  Parkinson disease 10
PARK12  Parkinson disease 12
PARK16  Parkinson disease 16
PARK2  Parkin RBR E3 ubiquitin protein ligase
PARK3  Parkinson disease 3 (autosomal dominant, 
Lewy body)
PARK7  Parkinsonism-associated deglycase
PCLO  Piccolo presynaptic cytomatrix protein
PINK1  PTEN-induced putative kinase 1
PLA2G6  Phospholipase A2 group VI
PPP1R8  Protein phosphatase 1 regulatory subunit 8
PPYR1  Neuropeptide Y receptor Y4
PSMG1  Proteasome assembly chaperone 1
RTN4R  Reticulon 4 receptor
RYR2  Ryanodine receptor 2
SEPT5  Septin 5
SLC5A7  Solute carrier family 5 member 7
SNAP29  Synaptosome-associated protein 29
SNCA  Alpha-synuclein
SYNJ1  Synaptojanin 1
SYT15  Synaptotagmin 15
TBX1  T-box 1
TCF3  Transcription factor 3
TH  Tyrosine hydroxylase
UCHL1  Ubiquitin C-terminal hydrolase L1
UPS  Ubiquitin proteasome system
USP32  Ubiquitin-specific peptidase 32
VPS35  VPS35 retromer complex component
WNT3  Wnt family member 3
5-HT2AR  Serotonin 2A receptor
Introduction
Parkinson’s disease (PD) is a progressive debilitating 
movement disorder, affecting approximately 1% of the 
population over 65 (Moore et al. 2005). The characteristic 
major motor symptoms derive from the profound and selec-
tive loss of dopaminergic neurons from substantia nigra 
pars compacta, coupled with an accumulation of round 
cytoplasmic inclusions (Lewy bodies) and dystrophic neu-
rites (Lewy neurites) in surviving neurons (Moore et al. 
2005). In more advanced stages, patients can also develop 
a range of nonmotor symptoms, including rapid eye move-
ment, sleep behavior disorder, constipation, depression 
and cognitive decline. Treatments aimed at compensating 
dopamine deficit (such as levodopa and deep brain stimula-
tion) can alleviate the motor symptoms but finally are not 
effective to halt or slow down disease progression (Toft and 
Ross 2010). Despite the molecular mechanisms underly-
ing PD are still far from being understood, the progressive 
deterioration of vulnerable dopaminergic neurons seems to 
arise from several cellular disturbances including protein 
misfolding and aggregation (Michel et al. 2016), synaptic 
damages, apoptosis, mitochondrial dysfunctions (Winkl-
hofer and Haass 2010), oxidative stress (Dias et al. 2013), 
impairment of the Ubiquitin/Proteasome System (UPS) 
(Betarbet et al. 2005) and neuroinflammation (Wang et al. 
2015) (Fig. 1).
PD was for a long time believed to be a typical non-
genetic disorder. When in 1997 Polymeropoulos and col-
leagues reported the first SNCA pathogenic mutation in the 
Italian Contursi kindred (Polymeropoulos et al. 1997), they 
revolutionized this view opening the way to new interest-
ing perspectives about the genetic contribution to this still 
incurable condition (Moore et al. 2005). From that moment, 
an increasing number of genetic loci and numerous risk 
factors have been discovered (Lewis and Cookson 2012; 
Bonifati 2014), starting from the familiar genes responsible 
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for the Mendelian inherited forms, such as the autosomal 
dominant genes (SNCA, LRRK2, VPS35, GBA), the typi-
cal recessive (PARK2, PINK1, PARK7) and the atypical 
recessive ones (ATP13A2, PLA2G6, FBXO7) (Klein and 
Westenberger 2012). Despite the existence of these rare 
monogenic forms, it is now clear that PD is a genetically 
heterogeneous and most likely complex disorder, often 
complicated by incomplete penetrant traits and variable 
expressivity. The list of candidate genes is continuously 
updated (Bonifati 2014; Lubbe and Morris 2014; Trinh and 
Farrer 2013), mainly thanks to the massive advancement in 
genomic biotechnologies that have allowed to detect hun-
dreds of pathogenic or susceptibility variants at the single 
nucleotide polymorphism (SNP) level. However, a lot of 
work still has to be done to identify additional sources of 
missing heritability or to assign a precise causal mecha-
nism to the growing number of discovered loci (Gamazon 
and Stranger 2015).
While SNPs and small indels constitute the most com-
monly investigated DNA variations, submicroscopic chro-
mosomal rearrangements, also known as Copy Number 
Variations (CNVs), are emerging as crucial players in the 
individual’s genomic architecture and in modeling com-
plex human diseases, including PD. However, the major-
ity of CNV association studies have been conducted using 
the traditional candidate-gene approach that, although 
provides valuable information on common variants, is 
inadequate to completely dissect the genetic background 
of polygenic multifactorial disorders like PD. The search 
for single-gene mutations has to be changed, turning into 
the need to assess the collective effect of common and rare 
variants that together may converge on PD pathology. In 
this context, the “systems biology” approach represents 
a worthwhile instrument to analyze complex biological 
systems, moving beyond the conventional gene-centric 
scheme, and finally generating a more defined molecular 
picture of PD.
Herein, we will review the most common CNV-altered 
genes and detail the current knowledge about their patho-
genic or susceptibility impact on PD pathobiology. Moreo-
ver, we will collect the set of rare individual CNVs reported 
so far in PD patients and analyze them by a “systems biol-
ogy” approach. This new perspective reveals these private 
CNVs cluster in common deregulated biological processes 
that could contribute to disease onset or progression, and 
opens the window to a new possible genetic scenario in the 
unsolved PD puzzle.
Copy number variations: a prevalent source 
of genomic variations
The DNA sequence of human genome is constantly chang-
ing and this process allows humans to evolve and adapt. 
The scientific community has long been aware of genetic 
variations of extreme size (i.e., cytogenetically recogniz-
able elements and SNPs) (Zarrei et al. 2015). However, 
about 10 years ago, scientists began to recognize abundant 
variations of an intermediate size class known as structural 
variations. Within this class, copy number variations rep-
resent the largest component by far. CNVs are defined as 
genomic segments showing copy number variability among 
individuals compared to a reference genome. The size of 
CNVs ranges from 50 bp to several Mb, with a significant 
drop of variant numbers in 50 bp to 1 kb range (MacDon-
ald et al. 2014). These structural variants can include either 
a single gene or a contiguous set of genes, encompassing 
more polymorphic base pairs than SNPs and finally result-
ing in an altered DNA diploid status (i.e., gain or loss of 
genomic region).
Depending on their size, CNVs can be measured by a 
multitude of laboratory testing methods, either targeting the 
whole genome (genome-wide level) or restricted to certain 
locations on chromosomes (locus-specific levels) (Fig. 2) 
(Cantsilieris et al. 2013). While targeted approaches such 
as FISH or quantitative PCR-based strategies have been 
long used in the past, the most advanced screenings rely 
on whole-genome applications, such as array Comparative 
Genomic Hybridization or Next-Generation Sequencing 
experiments. Both these biotechnologies have dramatically 
improved and catalyzed the detection and characterization 
of multiple CNVs, offering the simultaneous testing of 
thousands of loci with high reproducibility, high resolution, 
and scalability for complete mapping of imbalances (Carter 
et al. 2002; Shaw-Smith et al. 2004; Iafrate et al. 2004; 
Inazawa et al. 2004; Ishkanian et al. 2004). However, these 
Fig. 1  Schematic representation of molecular elements and common 
altered pathways underlying the complex PD puzzle
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whole-genome strategies still need post-experimental vali-
dations and, therefore, a gold-standard analysis for CNVs 
has not been defined yet.
CNVs are very common and arise in the presence of 
specific architectural genomic elements that render DNA 
regions very susceptible to rearrangements. Depending 
on whether the same rearrangement is identified in unre-
lated individuals, CNVs can be grouped as recurrent or 
non-recurrent events (Lee and Lupski 2006). The most 
common cause of recurrent genomic rearrangements is 
the non-allelic homologous recombination (NAHR) that 
occurs between two DNA blocks of high homology, like 
the region-specific low-copy repeats sequences (LCRs) 
(Fig. 3a). On the contrary, non-recurrent CNVs can result 
from non-homologous end joining (NHEJ) or fork stall-
ing and template switching (FoSTeS) mechanisms. NHEJ 
represents the major cellular mechanism for double-strand 
break repair: upon a double-strand break, NHEJ reconnects 
chromosome ends leaving random nucleotides at the site of 
the breakage to facilitate the strands’ alignment and ligation 
(Fig. 3b) (Ambroziak et al. 2015). FoSTeS occurs when 
the DNA replication machinery pauses, and the template is 
switched with another region in physical proximity to the 
original replication fork (Fig. 3c) (Lee et al. 2007). Such 
template switching may occur several times before the rep-
lication process gets back to its original template, resulting 
in complex rearrangements (Ambroziak et al. 2015).
CNVs can control phenotype in several ways: they can 
affect gene expression through the simple gene dosage 
effect, or through more intricate mechanisms such as inser-
tions and deletions of regulatory regions and alterations 
of chromatin architecture (Gamazon and Stranger 2015). 
In this regard, CNVs can interfere with a form of regula-
tory scaffold of the chromatin (the so-called Topologically 
Associating Domains or TADs) by disrupting or reposition-
ing boundaries and, therefore, constraining the enhancer 
or silencer activity with their target genes (Franke et al. 
2016). Similarly, CNVs in other non-coding regions may 
alter the normal rate and tissue-specific transcription pat-
tern of the neighboring, otherwise intact, genes by chang-
ing, for example, the affinity for transcription factors. This 
cis-acting effect of non-coding variations has been recently 
Fig. 2  CNVs can be measured by a spectrum of laboratory meth-
ods targeting specific locations on chromosomes (locus-specific lev-
els), or the whole genome (genome-wide level). These numerous 
methodologies are characterized by different levels of resolutions. 
The locus-specific techniques encompass (1) PCR-based strategies, 
such as quantitative real-time PCR (qPCR), Multiplex Ligand Probe 
Amplification (MLPA) or multiplex amplifiable probe hybridization 
(MAPH); (2) the Fluorescence in situ Hybridization (FISH) assays 
and (3) the RFLP (restriction fragment length polymorphism—South-
ern blot analysis. The whole-genome methodologies include (1) the 
classical chromosomal G-bandage (karyotyping); (2) the aCGH 
(Comparative Genomic Hybridization array) platforms and (3) the 
NGS (Next-Generation sequencing) technology. These two latter are 
increasingly replacing both the classical detections methods and the 
locus-specific techniques
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demonstrated for a SNP in a distal enhancer element regu-
lating the expression of SNCA (Soldner et al. 2016). Some 
representative pictures about the mechanisms of non-
coding variants and their implication in human genetics 
are reported in a number of excellent reviews (Spielmann 
and Mundlos 2016; Lupianez et al. 2016; Spielmann and 
Mundlos 2013), which the reader is referred to.
All together, CNV alterations may account for adap-
tive or behavioral traits, may have no phenotypic effects 
or can underlie diseases. For this reason, determining the 
clinical significance of CNVs is very challenging and 
comprehensively relies on frequency information from 
healthy control cohorts, hereditability, size, gene content, 
type (copy number state) and location on chromosome 
(interstitial, centromeric or repeat-regions) (Hehir-Kwa 
et al. 2013).
Notwithstanding the difficulties in interpreting quan-
titative data, specific large CNVs and single-gene dosage 
alterations have emerged as critical elements for the devel-
opment and maintenance of the nervous system (Gu and 
Lupski 2008) and have appeared to contribute to heredita-
ble or sporadic neurological diseases, such as neuropathies, 
epilepsy forms, autistic syndromes, psychiatric illnesses 
and also neurodegenerative diseases, including PD (Lee 
and Lupski 2006; Kalman and Vitale 2009; Hoyer et al. 
2015; Olson et al. 2014; Grayton et al. 2012; Wang et al. 
2013).
In the next paragraphs, we will focus on the current evi-
dence about the occurrence of CNVs in familiar PD genes 
by highlighting strengths and weaknesses of interpretations 
for diagnosis and biomarkers usefulness. Moreover, we 
will collect from published literature the currently known 
set of rare CNVs observed in PD patients and analyze them 
through a systems biology point of view, in order to assess 
their biological role, their interactions and the possible 
functional impact on PD pathobiology.
Copy number variations in familiar PD genes
SNCA
SNCA (alpha-synuclein) represents the most convincing 
locus causing both familiar and sporadic PD. This gene 
Fig. 3  Schematic illustration of the three most common events 
causing genomic rearrangements. a NAHR generates CNVs when 
genomic segments with high sequence similarity (direct low-copy 
repeats sequences, green arrows) recombine. This recombination 
can generate a duplication of the similar locus (red arrow) on one 
chromosome, while removing the copy from the other. b Double-
stranded breaks (DBS) in DNA sequence recruit NHEJ-associated 
proteins to repair and ligate DNA strands together. First, end-repair 
protein replaces lost nucleotides on the double-strand break and DNA 
ligase associates broken DNA fragments together. If fragments from 
different chromosomes ligate together, duplications or deletions of 
sequence can occur. c After the original stalling of the replication fork 
(black line), the lagging strand disengages and anneals to a second 
fork (blue line), followed by extension of the now ‘primed’ second 
fork and DNA synthesis. After the fork disengages, the tethered origi-
nal fork with its lagging strand (black and blue lines) could invade 
a third fork (green line). Serial replication fork disengaging and lag-
ging strand invasion could occur several times (e.g., FoSTeS × 2, 
FoSTeS × 3, etc.) before resumption of replication on the original 
template. It should be noted that the CNVs created through FoSTeS 
are difficult to be distinguished from those generated by micro-
homology-mediated breakpoint-induced repair (MMBIR), a mecha-
nism of end-joining that relies on small-scale homology of DNA 
sequence at the ends of DSBs
18 Hum Genet (2017) 136:13–37
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encodes a small natively unfolded presynaptic protein that 
aggregates in Lewy bodies and Lewy neurites, the patho-
logical hallmark lesions of PD (Stefanis 2012). As we will 
discuss here below, SNCA is the best example of dosage-
dependent toxicity: the more alpha-synuclein you have, the 
worse will be PD.
The first genomic triplication of SNCA was observed 
within the Spellman–Muenter family (better known as Iowa 
Kindred), a large family with autosomal dominant inherit-
ance transmission of PD and dementia (Singleton et al. 
2003). Later, several families with different ethnic back-
ground have been described, including members carry-
ing four copies (triplication) or three copies (duplication) 
of SNCA (Table 1) (Wang et al. 2013; Keyser et al. 2010; 
Sekine et al. 2010; Kojovic et al. 2012; Darvish et al. 2013; 
Olgiati et al. 2015; Ferese et al. 2015; Uchiyama et al. 2008; 
Ahn et al. 2008; Nishioka et al. 2006, 2009; Chartier-Har-
lin et al. 2004; Ibanez et al. 2004, 2009; Sironi et al. 2010; 
Pankratz et al. 2011; Elia et al. 2013; Konno et al. 2016; 
Ross et al. 2008; Kara et al. 2014; Mutez et al. 2011). In 
general, triplication generates very high expression of 
mRNA and protein molecules and influences the clinical 
manifestations of PD, causing severe forms of Parkinsonism 
similar to dementia with Lewy body. In contrast, the clinical 
phenotype of patients with duplicated SNCA resembles idi-
opathic PD, mainly with late age at onset, good efficacy for 
levodopa therapy, slower disease progression and without 
early development of dementia.
An interesting familiar pedigree, the “Lister fam-
ily”, presents both duplicated and triplicated SNCA car-
riers within different branches of the pedigree (branches 
J and I), suggesting a primary duplication event followed 
later by another one and resulting in the triplication (Far-
rer et al. 2004; Fuchs et al. 2007). Similarly, the Ikeuchi 
family has both heterozygous and homozygous duplication 
carriers born from a consanguineous marriage (producing a 
pseudo-triplication) (Ikeuchi et al. 2008). The clinical fea-
tures of individuals with the SNCA homozygous duplica-
tion showed severe parkinsonism similar to that of triplica-
tion carriers.
Along with the familiar forms, a good percentage of 
sporadic PD patients carry de novo duplication of SNCA 
(Table 1) (Ahn et al. 2008; Garraux et al. 2012; Shin et al. 
2010; Troiano et al. 2008; Brueggemann et al. 2008; Nuyte-
mans et al. 2009). Generally, their clinical course is similar 
to typical sporadic PD without severe progression or cogni-
tive decline.
The breakpoint of SNCA multiplications is not the same 
in each patient. The largest multiplication detected so far 
is about 41.2 Mb, containing 150 genes and defined a par-
tial trisomy 4q (Garraux et al. 2012), while the smallest one 
counts about 0.2 Mb (Nishioka et al. 2009). The size and 
gene makeup of each multiplicated region do not seem to 
severely influence the clinical presentation of the carriers.
Interesting insights derive from the mosaicism condition 
of SNCA rearrangements. In this regard, two interesting PD 
cases have been described, which resulted negative to exon 
dosage test in peripheral blood, and positive for SNCA copy 
number changes on oral mucosa cells (Perandones et al. 
2014). Both patients displayed a parkinsonian clinical phe-
notype of SNCA copy number carriers. Starting from this 
evidence, authors suggest to take into consideration the 
possibility to examine cells from both peripheral lympho-
cytes and other tissues to detect low-grade mosaicism.
PARK2
Although SNCA story suggests a gain of function, several 
early-onset forms of PD have demonstrated the role of loss 
of function genes in the etiology of the disease. The most 
common loss-of-function mutations belong to Parkin (or 
PARK2) gene, one of the largest in our genome harbored in 
the long arm of chromosome 6 (6q25.2-q27) and encoding 
an E3 ubiquitin ligase. Mutations of PARK2 are particularly 
frequent in individuals with familiar recessive inheritance 
and account for 50% of the cases with autosomal recessive 
juvenile PD. Parkin mutations also explain ~15% of the 
sporadic cases with onset before 45 (Bonifati 2012; Luck-
ing et al. 2000) and act as susceptibility alleles for late-
onset forms of PD (2% of cases) (Oliveira et al. 2003).
PARK2 gene has a high mutation rate because it is 
located in the core of FRA6E site, one of the most muta-
tion-susceptible common fragile sites of human genome 
(Ambroziak et al. 2015). For this reason, more than 200 
putative pathogenic mutations have been reported so far, 
affecting numerous ethnic populations (Wang et al. 2010, 
2013; Keyser et al. 2010; Nuytemans et al. 2009; Chaud-
hary et al. 2006; Klein et al. 2005; Shadrina et al. 2007; 
Choi et al. 2008; Pankratz et al. 2009; Kay et al. 2010; 
Guerrero Camacho et al. 2012; Moura et al. 2012; Yonova-
Doing et al. 2012; Chu et al. 2014; Al-Mubarak et al. 2015; 
Guo et al. 2015; Mata et al. 2005). The PARK2 mutation 
spectrum includes homozygous or compound heterozy-
gous missense and nonsense point mutations, as well as 
several exon rearrangements (both duplications and dele-
tions) involving all the originally cloned 12 exons and the 
promoter region. Recently, our research group has outlined 
a complex alternative splicing mechanism regulating the 
expression of PARK2 (La Cognata et al. 2014, 2016; Scu-
deri et al. 2014). These data suggest that five additional 
exons exist, which, however, have never been considered 
for mutational or dosage screening. Overall, currently 
known Parkin CNVs are summarized in Fig. 4 and are col-
lected in the Parkinson Disease Mutation database (http://
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www.molgen.vib-ua.be/PDMutDB), which the reader is 
referred to for more details.
CNV rearrangements involving PARK2 exons account 
for 50–60% of all pathogenic anomalies, rendering gene 
dosage assays essential in parkin mutational screening 
(Kim et al. 2012). However, the hotspot nature of this gene 
makes its quantitative analysis a particular challenge, and 
several issues need to be pointed out in this regard. First, 
the determination of mutational phase of the rearrange-
ments, meaning the assessment that amplified or deleted 
exons are really contiguous. Phase determination seems 
to be a fundamental requisite for PARK2 molecular diag-
nosis: by phase determination, several patients with appar-
ent contiguous multi-exon deletions were re-diagnosed 
as compound heterozygotes (Kim et al. 2012). A second 
important point refers to breakpoint mapping which can be 
useful to compare exon rearrangements between patients 
and families and to study the possible causing event mecha-
nism (Elfferich et al. 2011). Just a few number of papers 
have addressed this issue so far, but mostly report rear-
rangements into the region between PARK2 exons 2 and 8 
(Ambroziak et al. 2015; Elfferich et al. 2011). In the major-
ity of mapped cases, micro-homologies at breakpoint junc-
tions were present, thus supporting NHEJ and FoSTeS as 
the major mechanisms responsible for PARK2 genomic 
rearrangements (Ambroziak et al. 2015). Moreover, some 
data underpin the possible effects of ancient common 
founder in minor ethnic groups (Periquet et al. 2001). For 
example, microsatellite markers analysis in four families 
from The Netherlands have shown that a common haplo-
type of 1.2 Mb could be distinguished for the exon 7 dupli-
cation and a common haplotype of 6.3 Mb for the deletion 
of exon 4, suggesting common founder effects for distinct 
large rearrangements in parkin (Elfferich et al. 2011).
A relevant matter of ongoing debates is the pathogenic 
role of single heterozygous PARK2 CNVs. Several studies 
have sought to address this issue, but the findings published 
so far are controversial and conflicting. Some reports indi-
cate that CNVs heterozygous mutations in PARK2 associ-
ate with increased PD risk (Pankratz et al. 2011; Pankratz 
et al. 2009; Huttenlocher et al. 2015), while others found 
no differences for association (Wang et al. 2013; Kay 
et al. 2010). In addition, examinations of family pedigrees 
revealed heterozygous members with mild late-onset PD 
(Klein et al. 2000; Farrer et al. 2001), or without typical 
clinical signs of the disease (Wang et al. 2013).
PINK1
Pathogenic mutations in PINK1 (PTEN-induced kinase 
gene) are a less common cause of early-onset PD with a 
frequency variable from 1 to 9% depending on the ethnic 
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is a putative serine/threonine kinase of 581 amino acids 
involved in mitochondrial quality control and oxidative 
stress (Valente et al. 2004).
Homozygous and compound heterozygous deletions 
involving different combinations of exons 4–8 have been 
described in both familial and sporadic early-onset cases 
coming from Japan, Brazil, Sudan and Iran (Table 2) 
(Darvish et al. 2013; Atsumi et al. 2006; Li et al. 2005; 
Camargos et al. 2009; Cazeneuve et al. 2009). A breakpoint 
analysis has been performed just in one of these patients, 
revealing a complex rearrangement involving the neighbor-
ing DDOST gene and maybe resulting from FoSTeS mech-
anism (Cazeneuve et al. 2009). Moreover, single heterozy-
gous cases have been described, albeit these mutations do 
not completely explain the recessive inheritance pattern. 
The largest heterozygous deletion known so far (56 kb) 
includes the entire PINK1 genetic region, two neighbor-
ing genes, and two highly similar AluJo repeat sequences, 
which have been suggested as responsible for an unequal 
crossing-over (Marongiu et al. 2007). Further heterozygous 
deletions involving exons 1, 3–8 and exon 7 have been 
described in familial or sporadic cases of early-onset PD 
(Table 2) (Moura et al. 2012; Guo et al. 2010; Samaranch 
et al. 2010).
PARK7
PARK7 was the third gene identified in 2001 as respon-
sible of early-onset PD (Bonifati et al. 2003; van Duijn 
et al. 2001). It encodes a conserved multifunctional pro-
tein belonging to the peptidase C56 family (also called 
DJ1) which acts as a positive regulator of transcription, 
redox-sensitive chaperone, sensor for oxidative stress, and 
apparently protects neurons from ROS-induced apoptosis 
(Lev et al. 2006; Ariga et al. 2013; Xu et al. 2005).
The proof that PARK7 was a gene-causing disease 
came from a study on a Dutch family where members car-
ried a 14 kb homozygous deletion involving the first five 
of seven exons (Bonifati et al. 2003). Later, three siblings 
of Iranian origins born from consanguineous parents and 
carriers of a homozygous deletion of exon 5 have been 
reported (Table 3) (Darvish et al. 2013). Further heterozy-
gous CNVs (both deletions and duplication) involving the 
exons of DJ-1 gene have been published so far (Guo et al. 
2010; Hedrich et al. 2004; Djarmati et al. 2004; Macedo 
et al. 2009), although they do not completely explain the 
recessive pattern of the PD phenotype.
ATP13A2
ATP13A2 mutations are associated with Kufor-Rakeb syn-
drome (KRS), a form of recessively levodopa-responsive 
inherited atypical Parkinsonism (Vilarino-Guell et al. 
2009). This gene encodes a large protein belonging to 
the ATPase transmembrane transporters, and recently 
it has been identified as a potent modifier of the toxic-
ity induced by alpha-synuclein (Murphy et al. 2013). To 
our knowledge, just one family from Iran with deletion 
of ATP13A2 has been reported, including three affected 
siblings born from consanguineous parents and carriers of 
a homozygous deletion of exon 2 (Darvish et al. 2013). 
All three individuals presented moderate mental retarda-
tion, aggressive behaviors, visual hallucinations, supra-
nuclear vertical gaze paresis, slow vertical saccades and 
Fig. 4  Schematic representation of PARK2 genetic structure and 
currently identified CNVs in PD patients. All the canonical PARK2 
exons are involved in exons rearrangements. Red bars correspond 
to exons deletions, blue bars to duplications and green bars to trip-
lications. All depicted CNVs can be found at the Parkinson Disease 
Mutation database (http://www.molgen.vib-ua.be/PDMutDB)
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dystonia. Cognitive function deteriorated rapidly, and all 
of them developed dementia by age 10. Further clinical 
and genetic follow-up of KRS patients will increase the 
knowledge of the natural history and clinical features of 
this syndrome.
The 22q11.2 deletion
A separate speech deserves the 22q11.2 deletion that 
lately is receiving more and more attention in PD field. 
Deletions at 22q11.2 are classically associated with a het-
erogeneous range of clinical syndromes, overall named 
22q deletion syndrome (22qDS). The clinical phenotype 
of 22q deletion carriers varies widely, with multiple sys-
tem involvement, including cleft palate, dysmorphic facial 
features, cardiac defects, skeletal deformities, develop-
mental delays, learning disabilities and increased risk 
of developing schizophrenia and other mental disorders. 
Despite the multiple system involvement, the associa-
tion between 22q11.2 deletion and PD was not suspected 
until the publication of independent case reports of 
Table 2  All the current studies describing PINK1 copy number changes in PD
The CNVs mutation type, the size of the mutation, the ethnicity of patients, the phenotype and the methodological approaches to measure quan-
titative genomic variations are reported. The column F–S reports if described cases are familial or sporadic
CNVs overlapping PINK1 gene in PD
CNV type Size Ethnicity Phenotype Methodology F–S References
Homoz. deletion Exons 6–8 Japan Early-onset 
PD + dementia
n.a. F Li et al. (2005)
Homoz. deletion ~4600 bp Japan Early-onset PD n.a. n.a. Atsumi et al. (2006)
Heteroz. deletion ~56 kb Italy Definite PD qPCR, FISH, Microsat-
ellite markers analysis
S Marongiu et al. (2007)
Homoz. deletion Exon 7 Brazil Early-onset PD Sequencing, qPCR S Camargos et al. (2009)
Homoz. deletion 8669 bp (exons 4–8) Sudan Early-onset PD MLPA, sequencing F Cazeneuve et al. (2009)
Heteroz. deletion Exons 3-8 China Early-onset PD qPCR S Guo et al. (2010)
Heteroz. deletion Exon 7 Spanish Early-onset PD with LBs Sequencing, qPCR F Samaranch et al. (2010)
Compound heteroz. 
deletion
Exon 2 + exons 2–4 Iran Typical clinical features MLPA, qPCR S Darvish et al. (2013)
Homoz. deletion Exon 5 and exon 4 Typical clinical features 
and PD with dementia
F
Heteroz. deletion Exon 1 Brazil Early-onset PD MLPA, qPCR n.a. Moura et al. (2012)
Table 3  All the current studies describing PARK7 copy number changes in PD
The CNVs mutation type, the size of the mutation, the ethnicity of patients, the phenotype and the methodological approaches to measure quan-
titative genomic variations are reported. The column F–S reports if described cases are familial or sporadic
CNVs overlapping PARK7 gene in PD
CNV type Size Ethnicity Phenotype Methodology F vs. S References
Homoz. deletion Exons 1–5 
(14.082 bp)







F Bonifati et al. (2003)
Heteroz. deletion Exons 5–7 Caucasian (Tyrol, 
Austria)
Early-onset PD Quantitative duplex 
PCR
S Hedrich et al. (2004)
Heteroz. deletion Exon 5 Serbian Early-onset PD qPCR n.a. Djarmati et al. (2004)
Heteroz. duplication Exons 1–5 Dutch Early-onset PD MLPA, sequencing S Macedo et al. (2009)
Heteroz. deletion Exon 2 China Early-onset PD qPCR S Guo et al. (2010)
Homoz. deletion Exon 5 Iran Typical clinical 
features
MLPA, qPCR F Darvish et al. (2013)
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co-occurrence of parkinsonism in patients with 22q11.2 
deletion syndrome (Table 4) (Krahn et al. 1998; Zaleski 
et al. 2009; Booij et al. 2010).
The interest in this possible link increased after Butcher 
and colleagues reported four patients with early-onset PD 
in their study of 159 adults with 22q11.2 deletion syn-
drome, founding that the use of antipsychotics in these 
patients delayed diagnosis of PD, and assessing after 
autopsy examination the presence of typical Lewy bodies 
and Lewy neurite formations too (Butcher et al. 2013). A 
couple of months ago, Mok et al. (Mok et al. 2016) per-
formed the reverse experiment, namely pooling data from 
previous large PD case–control studies and assessing the 
frequency of 22q11.2 deletion carriers. Eight patients with 
PD and none of the controls had the deletion, providing a 
statistical significant association between the 22q deletion 
and an increased risk of developing the disease (Table 4). 
In accordance with this result, a single case report from 
Virginia describes a 37-year-old early-onset PD patient car-
rying the 22q11.2 deletion but without any features of typi-
cal 22qDS (Rehman et al. 2015). All together, this evidence 
suggests 22q11.2 deletion might underlie early-onset PD, 
warning clinicians to take into consideration this genetic 
test as part of their evaluation for patients with early-onset 
PD.
The chromosome 22q11.2 region contains some excel-
lent candidate genes for PD: COMT (or Catechol-O-Meth-
yltransferase), a key regulator of synaptic dopamine levels 
and a target of inhibitory drugs for the treatment of wear-
ing-off phenomena in PD patients (Muller 2015); SEPT5, 
a vesicle- and membrane-associated protein playing a sig-
nificant role in inhibiting exocytosis, as well as a parkin 
substrate (Son et al. 2005; Marttinen et al. 2015); DGCR8 
that encodes a complex subunit involved in the biogenesis 
of microRNAs, including miR-185 which is predicted to 
target LRRK2 (Ogaki and Ross 2014).
Interestingly, Perandones et al. (2015) reported a case 
of mosaicism of a patient from the Ashkenazi Jewish eth-
nic group with a history of midline defects and PD onset 
at 46 years (Table 4). In this patient, FISH test detected 
a mosaicism of the 22q deletion in 24% of the analyzed 
blood cells, highlighting the relevance of performing indi-
vidual cell-by-cell analysis.
High‑throughput whole‑genome studies to map 
CNVs in PD
The major reported PD-linked CNVs have actually been 
ascertained through single-gene investigations, and 
received most of the attention because of their already-
known or hypothesized role in the disease. However, these 
mutations account only for a limited number of PD, and the 
vast majority of cases continue to remain without a valid 
explanation. Thanks to the rapid advancement of biotech-
nologies, scientists are now able to scan entirely the human 
genome, producing high-quality ultradense genotypes and 
fast localization of genomic deletions and duplications. 
However, their applications in PD field are still not numer-
ous, and only a few studies have investigated the overall 
contribution of global CNVs on PD etiology (Pankratz 
et al. 2011; Simon-Sanchez et al. 2008; Liu et al. 2013; 
Pamphlett et al. 2012; Bademci et al. 2010).
The first pilot analysis assessing the role of struc-
tural genetic variations in risk for PD was carried out in 
a population of 276 unique and unrelated Caucasian indi-
vidual with PD using two genome-wide SNP genotyping 
platforms and corrected metrics for CNVs interpretation 
(Simon-Sanchez et al. 2008). In this study, along with sev-
eral PARK2 deletions and duplications confirmed by inde-
pendent gene dosage experiments, a total of 182 genomic 
duplications and 161 heterozygous/homozygous deletions 
were measured, but no statistically significant regions asso-
ciated with PD were identified. Among these CNVs, a sub-
group (38 duplications and 44 deletions) was revealed only 
in patients and not in healthy controls or in DGV reposi-
tory (http://dgv.tcag.ca/dgv/app/home), a web database col-
lecting CNV alterations observed in the normal population 
(Supplementary Table 1).
Some years later, Pankratz et al. (2011) presented the 
results of a systematic CNV genome-wide analysis per-
formed using two CNV calling algorithms (PennCNV 
and QuantiSNP), two different association strategies (cen-
tric position and 400 kb window) and multiple filters to 
improve the quality of CNVs calls. By intersection of 
results from all these criteria, they were able to replicate 
the association of PD susceptibility with PARK2 CNVs, 
and then revealed two novel genes (DOCK5 and USP32) 
associated with an increase in risk for PD at genome-wide 
significance (unfortunately not confirmed by independ-
ent molecular tests). Also in this study, a set of altered 
genetic regions were unique of PD patients (Supplementary 
Table 1).
To identify novel CNVs and to evaluate their contribu-
tion to PD, Liu et al. (2013) conducted a CNVs genome-
wide scan in a case–control dataset (268 PD cases and 178 
controls), focusing on a genetic isolate, the Ashkenazi Jew-
ish population. Using high-confidence CNVs, they exam-
ined the global genome-wide burden of large and rare 
CNVs: this analysis did not reveal significant differences 
between cases and controls, but deletions were found 1.4 
times more often in cases than controls. Interestingly, sev-
eral rare genic CNVs were present in patients and absent in 
controls (Supplementary Table 1). Among these, the dupli-
cation of OVOS2 (ovostatin 2, a gene of unknown func-
tion) was classified as significant risk factors for PD. Other 
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interesting PD-related CNVs alterations encompassed 
NSF and WNT3 genes (later better discussed), and ATXN3, 
FBXW7, CHCHD3, HSF1, KLC1, and MBD3, which par-
ticipate in the PD disease pathways.
An unusual approach was carried out by Pamphlett et al. 
(2012), who investigated the existence of somatic candidate 
genetic CNVs in PD brains and missing in blood DNA. A 
total of 45 PD-brain-specific CNVs was found, some of 
which overlap with DGV regions. Candidate genes (not 
in controls nor in DGV) included BCL2 involved in mito-
chondrial function and apoptosis (discussed in the follow-
ing paragraphs), NRSN1 implicated in cellular vesicle for-
mation, and RYR2 which participates in cellular calcium 
release (Supplementary Table 1). This study shows that 
specific brain CNVs can be detected, and raises the pos-
sibility that brain-situated mutations could underlie some 
cases of PD.
A systems biology approach for rare and singleton 
CNVs
Altogether, genome-wide studies have revealed the exist-
ence of multiple genetic loci containing rare o singleton 
copy number changes in PD and not reported in control 
cohorts (Supplementary Table 1). Although less frequent, 
these rare CNVs could represent potentially functional 
variants exerting small effects on PD pathogenesis, but not 
emphasized by single-gene investigations or association 
studies because do not reach a significant level of accept-
ance. These studies, in fact, are not the ideal approach for 
polygenic multifactorial diseases, where the pattern of 
allelic architecture could consist of hundreds of suscepti-
bility loci acting together by modulating the disease itself. 
To overcome some of these limits, the systems biology per-
spective can be used to assess, in a comprehensive man-
ner, the collective effect of these variants on PD outcome 
(Fig. 5).
Interestingly, the Gene Ontologies (GO) enrich-
ment of the total CNV-driven genes observed in PD 
patients until now reveals common deregulated bio-
logical processes (Fig. 6) mainly related to nervous sys-
tem functions and morphogenesis and including brain 
development (p value = 2.137E−7), regulation of neu-
rotransmission (p value = 5.465E−7), neuronal signal 
transduction (p value = 2.137E−6) and social behavior (p 
value = 3.958E−7). Moreover, several potential relation-
ships occur between rare CNV-affected genes and the cur-
rently known Mendelian PD genes (SNCA, LRRK2, GBA, 
PARK2, PINK1, DJ1, VPS35, ATP13A2, PLA2G6, FBXO7, 
UCHL1, MAPT). As shown in Fig. 7, specific and mean-
ingful associations exist (i.e., proteins jointly contribute to 
a shared function, but this does not necessarily mean they 
are physically binding each other), and some rare CNV-
affected genes could represent direct or indirect targets of 
Mendelian genes.
The global contribution of rare and singleton CNV-
driven genes to nervous system pathophysiology and func-
tions is also mirrored by the fact that, among those coin-
ciding with the MIM MORBID/ORPHANET records, 
more than 50% are involved in syndromes with altered 
phenotypic nervous features, including ataxia conditions, 
neuropathies, dystrophies, learning and development dis-
abilities and sensorineural disorders (Supplementary 
Table 2). All together, these findings support the evidence 
that uncommon individual CNVs may exert a susceptibility 
effect on PD, and strengthen the effectiveness of a systems 
biology approach to dissect complex multifactorial geneti-
cally heterogeneous diseases like PD.
Below, we will briefly discuss the GO-enriched rare 
genes by grouping them into three main categories (Syn-
aptic trafficking and neurotransmission, Brain development 
and cell fate differentiation, Cognitive impairment). GO-
enriched genes are graphically illustrated in Fig. 8.
Synaptic trafficking and neurotransmission
Synapses are specialized junctions of the central nervous 
system through which neurons connect each other to form 
extensive neural circuits. Synaptic functioning depends 
on a constant supply of energy and resources, essential 
for both neurotransmitters production and intracellular 
trafficking via repeated synaptic vesicle cycles. Altera-
tions in synaptic stability result in a disruption of the 
neuronal networks, a common hallmark of several neuro-
degenerative conditions, including PD, Huntington’s and 
Alzheimer’s.
Along with the previously described COMT, some rare 
CNV-altered genes are involved in synaptic neurotrans-
mission. One of the most interesting is the deletion of the 
entire TH (Tyrosine hydroxylase) gene, detected in a PD 
patient without evidence for dystonia but responsive to 
L-DOPA treatment, and in none of the controls (Supple-
mentary Table 1) (Bademci et al. 2010, 2012). TH encodes 
a monooxygenase that catalyzes the conversion of l-tyros-
ine to L-dihydroxyphenylalanine (L-DOPA), the rate-lim-
iting step in dopamine biosynthesis. Consistent with the 
essential role of TH in dopamine homeostasis, missense 
mutations in TH have been previously investigated, pro-
viding links with severe Parkinsonism-related phenotypes, 
such as Segawa’s syndrome, L-DOPA-responsive infantile 
Parkinsonism, or L-DOPA-responsive dystonia (DRD) in 
the recessive form (Bademci et al. 2012).
CNV-affected genes could alter not only dopamine 
metabolism but also other neurotransmitters’ signaling 
pathways. Convergent evidence agrees for early alterations 
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in the cholinergic system in PD (Bohnen and Albin 2011; 
Muller and Bohnen 2013). In this regard, CNVs in the 
BChE gene, a nonspecific cholinesterase enzyme that 
hydrolyses many different choline-based esters, and in the 
synaptic choline transporter SLC5A7 have been reported in 
some PD patients (Supplementary Table 1). Moreover, glu-
tamate plays a central role in basal ganglia circuitry, some-
times modulated by dopamine itself. Genetic variations 
Fig. 5  From a single-gene mutation perspective to a “systems biology” approach to dissect complex multifactorial diseases and improve the 
comprehension of the molecular basis underlying PD pathogenesis
Fig. 6  Gene ontologies (GO) enrichment analysis of PD-specific 
CNV loci reveals biological processes relevant for PD pathogen-
esis. a Representation of the top ten most significantly enriched 
(FDR < 0.05) canonical GO biological processes associated with can-
didate PD genes with copy number alterations (not reported in con-
trols or DGV). The analysis was performed using MetaCore platform 
(GeneGo, Thompson Reuters). The list is arranged in descending 
order with the most significant biological process at the top. Detailed 
information about the entire list of CNVs and overlapping genes 
are reported in Supplementary Table 1. p values have been obtained 
through hypergeometric analysis and corrected by FDR (false discov-
ery rate) method. b Pie chart representing the percentage of genes 
with altered copy number in PD belonging to the top ten enriched 
(p < 0.05) GO Biological Processes
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in the glutamate receptors GRID1, observed in some PD 
patients, could conceivably affect either the risk of develop-
ing PD or the phenotype.
DLG1, observed deleted in a PD patient, encodes a 
multi-domain scaffolding protein acting in septate junction 
formation, signal transduction, cell proliferation and synap-
togenesis. Interestingly, this gene was identified as differen-
tially expressed in the blood of PD patients vs. controls and 
was suggested at high confidence as candidate biomarker 
for PD (Sun et al. 2014). Moreover, recent studies have 
highlighted the role of DLG1 in the regulation of 5-HT2AR 
endocytosis and signaling (Dunn et al. 2014).
Several genes working in the synaptic vesicular cargo 
trafficking are affected by CNV alterations, such as SEPT5 
and SNAP29 (both overlapping the 22q11.2 deletion), NSF, 
SYT15, PCLO, and KLC1. A particular focus deserves 
NSF (also known as N-ethylmaleimide sensitive factor), 
previously identified as “top-hit” in a large GWAS meta-
study (rs183211) (Liu et al. 2011). While NSF functions 
in vesicular trafficking, membrane fusion, and synaptic 
neurotransmission are well documented, some recent stud-
ies also suggest a direct interaction between NSF and the 
Dopamine D1 receptor (D1R) (Chen and Liu 2010). This 
gene was also experimentally showed to be the directed tar-
get of miR-4519, a microRNA whose genetic variants are 
strongly associated with PD (Ghanbari et al. 2016).
An interesting deletion concerns the ADCYAP1 gene, 
encoding the pleiotropic bioactive peptide PACAP (or 
pituitary adenylate cyclase-activating polypeptide). PACAP 
is considered a potent neurotrophic and neuroprotective 
factor, playing an important role during the embryonic 
development of the nervous system, and protecting neu-
rons against toxic insults and neurodegeneration (Reglodi 
et al. 2011; Lee and Seo 2014). In the specific case of PD 
pathology, PACAP has been demonstrated to safeguard 
in vitro PD cell model against both salsolinol-induced 
and inflammatory-mediated toxicity (Brown et al. 2013, 
2014), to protect rat dopaminergic neurons after injection 
Fig. 7  Potential protein–protein interactions among rare PD CNVs 
and the currently known Mendelian genes as shown by STRING 
Software v.10 (http://string-db.org/) with high confidence settings 
(0.700 as minimum interaction score). The legend displays the mean-
ing of nodes and edges
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of 6-OHDA into the substantia nigra (Reglodi et al. 2004), 
and to prevent Parkinson-like neuronal loss and motor defi-
cits induced by prostaglandin J2 (Shivers et al. 2014).
Further genes founded CNV-altered and involved in syn-
aptic functions include ion channels (KCNJ12), biochemi-
cal enzymes (NAT8L, PPP1R8) and receptors (RTN4R).
Brain development and cell fate determination
Brain development is an orchestrated, tightly regulated, 
and genetically programmed process with influences from 
the environment. Alterations in genes regulating differen-
tiation, elaboration, and maintenance of neuronal cells can 
compromise neural specification events and cellular home-
ostasis, turning into neurodevelopmental abnormalities and 
neurodegenerative diseases (Mehler and Gokhan 2000).
Despite dopaminergic neurons cell death represents the 
leading event in PD pathology, it also physiologically occurs 
in developing brain during embryogenesis (van der Heide 
and Smidt 2013). The proper development of dopaminergic 
system requires the action of BCL2 family members, respon-
sible for dictating cell survival or commitment to apoptosis 
(van der Heide and Smidt 2013). In this regard, a somatic 
deletion in BCL2 has been observed in the brain of a PD 
patient in a homozygous state (Supplementary Table 1), 
likely producing deleterious effects on gene function.
Neuronal migration, differentiation, and death during 
brain development is also carefully tuned by a vast reper-
toire of growth and transcription factors, such as LHX1 and 
IGF1R, observed duplicated in PD patients (Supplemen-
tary Table 1). LHX1 encodes a transcription factor involved 
in axonal guidance and neurogenesis, and its overexpres-
sion has been demonstrated to inhibit the correct mesen-
cephalic dopaminergic neurons differentiation (Nakatani 
et al. 2010). IGF1R produces the tyrosine kinase receptor 
for the IGF1 (insulin-like growth factor) signaling pathway. 
This pathway was found dysregulated in a previous cross-
sectional transcriptomic analysis performed on PD datasets 
(Sutherland et al. 2009), and IGF1 signaling inhibitors have 
been proposed as promising therapies for the treatment 
Fig. 8  Interaction map representing CNV-altered genes enriched in 
GO classes and grouped on the basis of their main biological pro-
cesses. The map was created using the MetaCore Pathway Map Crea-
tor tool (GeneGo, Thompson Reuters). Detailed information about 
type of CNV, chromosomal size and study references are reported in 
Supplementary Table 1
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of various late-onset neurodegenerative disorders (Cohen 
2011). Moreover, the IGF1R reduction per se triggers pro-
tective effects in neurodegenerative conditions (Biondi 
et al. 2015), suggesting that its duplication could have a 
deleterious impact on neuronal life.
Members of the WNT family are additional factors 
expressed and secreted in the midbrain, involved in regu-
lation of cell fate and patterning during embryogenesis. 
Among WNT family members, a singleton deletion in WNT3 
has been described in PD (Supplementary Table 1). WNT3 
is located near MAPT locus and, according to previous 
genome-wide association studies, variations in its genetic 
regions can influence the risk of developing PD (Liu et al. 
2011; Simon-Sanchez et al. 2009). Moreover, the WNT/β-
catenin signaling pathway is able to control the dopaminer-
gic cell commitment in the midbrain, and is mediated by sev-
eral transcription factors of TCF family (Chen 2013), such as 
TCF3 observed deleted in PD (Supplementary Table 1).
Another interesting rare CNV-affected gene is ABL1 
(Supplementary Table 1), which encodes the tyrosine 
kinase protein c-Abl controlling neurogenesis, neurite out-
growth, and neuronal plasticity. Several lines of evidence 
suggest that aberrant activation of c-Abl plays an impor-
tant role in PD pathogenesis: (1) c-Abl is upregulated in 
postmortem striatum of PD patients and its phosphoryla-
tion at Tyr412 is enhanced in substantia nigra and striatum; 
(2) c-Abl phosphorylates parkin and impairs its E3 ligase 
activity, leading to loss of dopaminergic neurons in SN; 
(3) c-Abl regulates the clearance of α-syn, catalyzing its 
phosphorylation mainly at Tyr39 and to a lesser extent at 
Tyr125; (4) the inhibition of c-Abl activity by several drugs 
(imatinib/Gleevec, nilotinib/Tasigna, bafetinib/INNO-406) 
protects against the loss of dopaminergic neurons in wild-
type mice (Mahul-Mellier et al. 2014).
Additional CNV-altered genes, involved in brain devel-
opment, neuronal migration, and synaptic plasticity, 
include G-coupled proteins (FPR3, PPYR1), transcription 
factors and coactivator (HNF1B, GRIP1), elements of ubiq-
uitin/proteasome system (CUL5, PSMG1) and a member of 
the rhoGAP family (DLC1).
Cognitive impairment
The core feature of cognitive decline associated with PD is 
represented by an impairment of executive functions. Defi-
cits in planning, sequencing, and execution of complex-
goal-directed behavior are usually reported; working mem-
ory, episodic memory, procedural learning and attention are 
compromised with the presence of attentive fluctuations 
(Calabresi et al. 2006).
A set of rare CNV-altered genes are involved in learning, 
behavior and cognitive dysfunctions, including NRXN1, 
CNTNAP2, GRN, TBX1, GNB1L and DACH1.
Neurexin 1, encoded by NRXN1, is a presynaptic neu-
ronal adhesion molecule that interacts with postsynaptic 
neuroligins in both glutamatergic and GABAergic syn-
apses, and is important in synaptic specification and effi-
cient neurotransmission. Deletions and point mutations 
in NRXN1 are associated with a broad spectrum of neu-
ropsychiatric and neurodevelopmental disorders, includ-
ing autism, intellectual disability, epilepsy, developmen-
tal delay, and schizophrenia (Jenkins et al. 2014). Like 
NRXN1, also CNTNAP2 belongs to neurexin superfamily 
and encodes a neuronal transmembrane protein involved in 
neural-glia interactions and clustering of potassium chan-
nels in myelinated axons. Variations in this gene have been 
involved in susceptibility to neurodevelopmental disorders 
and language impairment (Infante et al. 2015). Moreover, 
downregulation of CNTNAP2 has been associated with 
AD and PD conditions (Infante et al. 2015; van Abel et al. 
2012). It has been suggested that neurexins–neuroligins 
level fluctuations sway the balance between excitatory and 
inhibitory neurotransmission, leading to damage of syn-
apses and dendrites and maybe triggering protein aggre-
gates in neurodegenerative conditions (Sindi et al. 2014).
GRN encodes progranulin, a multifunction protein 
widely distributed throughout the central nervous system 
primarily in neurons and microglia, and a potent autocrine 
neurotrophic factor and regulator of neuroinflammation 
(Van Kampen et al. 2014). Its loss-of-function mutations 
are known to be responsible for FTLDU-17 (ubiquitin-
positive frontotemporal lobar degeneration linked to chro-
mosome 17) and increase the risk for both Alzheimer’s and 
PD, suggesting important roles of progranulin in neurode-
generative processes (Chen et al. 2015). A deletion of GRN 
exons 1–11, resulting from a non-homologous recombina-
tion event, has been observed in a patient with typical GRN 
neuropathology, and in his sister presenting PD (Rovelet-
Lecrux et al. 2008). Moreover, it has been recently dem-
onstrated that progranulin gene delivery protects dopamin-
ergic neurons in a PD model, suggesting that GRN gene 
therapy may have beneficial effects in the treatment of PD 
(Van Kampen et al. 2014).
Other CNV-driven genes include TBX1 and GNB1L, 
both overlapping the 22q11.2 deletion, which have been 
associated with neuropsychiatric disorders such as schizo-
phrenia and autism (Chen et al. 2012; Ishiguro et al. 2010; 
Hiramoto et al. 2011).
Conclusions
A number of evidence suggests an extensive and complex 
genetic action of CNVs on PD etiopathogenesis. Thus far, 
unfortunately, only a small portion of the genetic variance 
has been identified; the remaining substantial components 
31Hum Genet (2017) 136:13–37 
1 3
remain unknown and urgently need to be addressed. One 
way we can move on is using “systems biology”, a worth-
while instrument to analyze complex biological processes 
and generate a more definite molecular picture of PD.
In this review, we showed that disregarded individual 
rare CNVs functionally act in common deregulated biologi-
cal processes relevant for PD pathogenesis and, therefore, 
potentially account for a portion of the “missing heritabil-
ity” underlying PD. The comprehensive detection and func-
tional characterization of rare CNVs in PD patients may 
be helpful to generate a more defined molecular picture of 
this complex disease, by revealing new candidate genes or 
disease-related molecular mechanisms, finally leading to 
improved diagnosis and counseling of mutation carriers. 
The forthcoming new era of genomics data promises to 
increase resolution and uncover new interesting clues.
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